Citadel Advisors’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Citadel Advisors’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,576	Closed	-$35.2K	–	14625
2025 Q4	$35.2K	Buy	30,576 +18,891	+162%	+$41.9K	﹤0.01%	12166
2025 Q3	$30.6K	Buy	+11,685	New	+$81K	﹤0.01%	12388

Other funds holding ZYBT

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Citadel Advisors's ZYBT Position: Q1 2026 in Review

Citadel Advisors sold out of Zhengye Biotechnology Holding (ZYBT) in Q1 2026, closing a stake of 30,576 shares — an estimated $35.2K sold.

Citadel Advisors first reported a position in ZYBT in Q3 2025 and held it in 2 quarters. The position peaked at $35.2K in Q4 2025. 8 funds tracked by Wall St. Rank hold ZYBT as of Q1 2026.

Citadel Advisors reported no remaining Zhengye Biotechnology Holding position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 30,576 Zhengye Biotechnology Holding shares in Q1 2026, an estimated $35.2K.
Citadel Advisors first reported a position in Zhengye Biotechnology Holding in Q3 2025 and held it in 2 quarters.
Citadel Advisors's Zhengye Biotechnology Holding position peaked at $35.2K in Q4 2025.
8 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.